Published in Mol Cancer on May 17, 2010
Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell (2010) 4.18
Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell (2011) 1.86
Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res (2011) 1.80
Myocardial AKT: the omnipresent nexus. Physiol Rev (2011) 1.76
Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget (2011) 1.52
Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene (2011) 1.50
MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. Gastroenterology (2013) 1.41
Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer (2011) 1.37
MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget (2014) 1.30
The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta (2012) 1.26
The roles of EZH2 in cell lineage commitment. Am J Transl Res (2011) 1.24
Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) (2011) 1.21
Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One (2012) 1.18
Transcriptional regulation of mammalian miRNA genes. Genomics (2010) 1.16
Regulation of microRNA expression and function by nuclear receptor signaling. Cell Biosci (2011) 1.12
Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs. BMC Cancer (2014) 1.12
High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat (2011) 1.12
PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer (2012) 1.11
MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma. Mol Cancer (2012) 1.08
Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS One (2011) 1.07
A highly expressed miR-101 isomiR is a functional silencing small RNA. BMC Genomics (2013) 1.05
Noncoding RNA in oncogenesis: a new era of identifying key players. Int J Mol Sci (2013) 1.03
miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration. Cell Cycle (2013) 1.03
EZH2, an epigenetic driver of prostate cancer. Protein Cell (2013) 1.02
Regulation of miR-200c by nuclear receptors PPARα, LRH-1 and SHP. Biochem Biophys Res Commun (2011) 1.01
Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One (2012) 0.98
Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Am J Pathol (2012) 0.98
Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica (2011) 0.97
Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cancer Biol Ther (2014) 0.95
Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia. Mol Med (2013) 0.94
Tumor hypoxia as a driving force in genetic instability. Genome Integr (2013) 0.92
Epigenetic effects of ethanol on the liver and gastrointestinal system. Alcohol Res (2013) 0.91
Roles of host and viral microRNAs in human cytomegalovirus biology. Virus Res (2010) 0.91
Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Med Res Rev (2015) 0.88
Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management. Onco Targets Ther (2013) 0.88
MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers. BMC Cancer (2014) 0.87
VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res (2014) 0.87
Polycomb repressive complex 2 regulates MiR-200b in retinal endothelial cells: potential relevance in diabetic retinopathy. PLoS One (2015) 0.86
MicroRNAs as putative mediators of treatment response in prostate cancer. Nat Rev Urol (2012) 0.86
MicroRNAs as predictive biomarkers and therapeutic targets in prostate cancer. Am J Clin Exp Urol (2014) 0.86
KSHV-Encoded MicroRNAs: Lessons for Viral Cancer Pathogenesis and Emerging Concepts. Int J Cell Biol (2012) 0.86
Emerging biomarkers of prostate cancer (Review). Oncol Rep (2012) 0.86
High-throughput sequencing of microRNAs in peripheral blood mononuclear cells: identification of potential weight loss biomarkers. PLoS One (2013) 0.85
Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2. Oncogene (2014) 0.85
An androgen receptor-microrna-29a regulatory circuitry in mouse epididymis. J Biol Chem (2013) 0.84
The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer. J Transl Med (2014) 0.84
Dysregulation of uterine signaling pathways in progesterone receptor-Cre knockout of dicer. Mol Endocrinol (2012) 0.84
The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. Oncotarget (2014) 0.84
The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth. Mol Cell Biol (2014) 0.83
Vitamin D and microRNAs in bone. Crit Rev Eukaryot Gene Expr (2013) 0.83
OxymiRs in cutaneous development, wound repair and regeneration. Semin Cell Dev Biol (2012) 0.83
Co-regulation of histone-modifying enzymes in cancer. PLoS One (2011) 0.83
Circulatory miR-628-5p is downregulated in prostate cancer patients. Tumour Biol (2014) 0.82
Identification of microRNA-mRNA functional interactions in UVB-induced senescence of human diploid fibroblasts. BMC Genomics (2013) 0.81
The Interactions of microRNA and Epigenetic Modifications in Prostate Cancer. Cancers (Basel) (2013) 0.81
MicroRNAs that affect prostate cancer: emphasis on prostate cancer in African Americans. Biotech Histochem (2013) 0.80
YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK. Br J Pharmacol (2014) 0.80
Alcohol-dysregulated miR-30a and miR-934 in head and neck squamous cell carcinoma. Mol Cancer (2015) 0.80
Celastrol Induces Autophagy by Targeting AR/miR-101 in Prostate Cancer Cells. PLoS One (2015) 0.79
MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells. J Cancer Res Clin Oncol (2016) 0.79
Epigenetic regulation of prostate cancer. Clin Epigenetics (2011) 0.79
Uncovering the roles of miRNAs and their relationship with androgen receptor in prostate cancer. IUBMB Life (2014) 0.79
Down-regulation of ARNT promotes cancer metastasis by activating the fibronectin/integrin β1/FAK axis. Oncotarget (2015) 0.79
Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role. Onco Targets Ther (2016) 0.79
The role of microRNAs in prostate cancer progression. Transl Androl Urol (2013) 0.77
MicroRNAs in Hyperglycemia Induced Endothelial Cell Dysfunction. Int J Mol Sci (2016) 0.77
The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells. J Biol Chem (2012) 0.77
MicroRNAs as New Characters in the Plot between Epigenetics and Prostate Cancer. Front Genet (2011) 0.77
A Fine-Tune Role of Mir-125a-5p on Foxn1 During Age-Associated Changes in the Thymus. Aging Dis (2017) 0.76
The complexity of epigenetic diseases. J Pathol (2015) 0.76
gga-miR-101-3p Plays a Key Role in Mycoplasma gallisepticum (HS Strain) Infection of Chicken. Int J Mol Sci (2015) 0.76
Glycolysis and EZH2 boost T cell weaponry against tumors. Nat Immunol (2015) 0.76
Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals. Anticancer Agents Med Chem (2016) 0.75
Role of androgen receptor splice variants in prostate cancer metastasis. Asian J Urol (2016) 0.75
Interference of kallikrein 1b26 (klk1b26) translation by microRNA specifically expressed in female mouse submandibular glands: an additional mechanism for sexual dimorphism of klk1b26 protein in the glands. Biol Sex Differ (2011) 0.75
One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling. Int J Mol Sci (2016) 0.75
microRNAs and Prostate Cancer. Adv Exp Med Biol (2015) 0.75
Fatty acid synthase is a primary target of MiR-15a and MiR-16-1 in breast cancer. Oncotarget (2016) 0.75
Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy. Prostate Cancer (2016) 0.75
Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. J Hum Genet (2016) 0.75
EZH2 enhances the differentiation of fibroblasts into myofibroblasts in idiopathic pulmonary fibrosis. Physiol Rep (2016) 0.75
The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
miRBase: tools for microRNA genomics. Nucleic Acids Res (2007) 38.61
Human MicroRNA targets. PLoS Biol (2004) 34.51
Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (2002) 24.31
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet (2002) 17.20
Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res (1998) 14.63
Identification of mammalian microRNA host genes and transcription units. Genome Res (2004) 14.63
A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet (2003) 12.16
Genome regulation by polycomb and trithorax proteins. Cell (2007) 11.96
Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites. Science (2008) 11.33
Role of histone H3 lysine 27 methylation in X inactivation. Science (2003) 9.85
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J (2003) 9.55
Androgen receptor in prostate cancer. Endocr Rev (2004) 7.92
The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev (2004) 7.89
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res (2006) 7.39
RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. Cell (2007) 7.06
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev (2004) 6.20
The conserved microRNA miR-8 tunes atrophin levels to prevent neurodegeneration in Drosophila. Cell (2007) 4.00
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res (2007) 3.82
Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science (2005) 3.80
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst (2003) 3.73
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A (2005) 3.24
A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A (2007) 3.15
MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood (2008) 3.03
Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell (2005) 3.01
The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood (2005) 2.99
Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res (2010) 2.82
MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis. J Biol Chem (2008) 2.81
Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst (1997) 2.51
MicroRNAs. Cancer J (2008) 2.28
MicroRNAs and cancer: profile, profile, profile. Int J Cancer (2008) 2.10
Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene (2004) 1.94
Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer (2006) 1.90
Drosophila UTX is a histone H3 Lys27 demethylase that colocalizes with the elongating form of RNA polymerase II. Mol Cell Biol (2007) 1.89
Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol (2005) 1.89
Polycomb recruitment to DNA in vivo by the YY1 REPO domain. Proc Natl Acad Sci U S A (2006) 1.82
The polycomb group protein EZH2 is required for mammalian circadian clock function. J Biol Chem (2006) 1.67
Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol (2008) 1.58
The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? Cancer Cell (2002) 1.56
miRNAs play a tune. Cell (2007) 1.48
EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate (2007) 1.34
Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J Cell Physiol (2008) 1.31
PIASy-mediated sumoylation of Yin Yang 1 depends on their interaction but not the RING finger. Mol Cell Biol (2007) 1.23
Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci (2005) 1.20
Yin Yang 1 regulates the transcriptional activity of androgen receptor. Oncogene (2009) 1.15
Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line. Carcinogenesis (1996) 1.06
PARP-1 modulates deferoxamine-induced HIF-1alpha accumulation through the regulation of nitric oxide and oxidative stress. J Cell Biochem (2008) 0.90
Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase. J Androl (2007) 0.82
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature (2011) 11.59
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature (2003) 6.48
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
A hierarchy of timescales in protein dynamics is linked to enzyme catalysis. Nature (2007) 5.78
Intrinsic motions along an enzymatic reaction trajectory. Nature (2007) 5.53
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
The POT1-TPP1 telomere complex is a telomerase processivity factor. Nature (2007) 5.08
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol (2008) 4.68
SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J (2007) 4.66
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med (2002) 3.68
Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med (2012) 3.21
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU. EMBO J (2003) 3.10
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet (2011) 2.70
Meta-analysis identifies common variants associated with body mass index in east Asians. Nat Genet (2012) 2.70
Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol (2006) 2.63
Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. Eur Urol (2011) 2.62
Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. Am J Hum Genet (2001) 2.61
Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet (2011) 2.51
Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet (2011) 2.48
DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate (2007) 2.37
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol (2012) 2.34
A shared docking motif in TRF1 and TRF2 used for differential recruitment of telomeric proteins. Science (2008) 2.30
Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res (2009) 2.27
Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst (2003) 2.26
Adipocyte NCoR knockout decreases PPARγ phosphorylation and enhances PPARγ activity and insulin sensitivity. Cell (2011) 2.26
Transient non-native hydrogen bonds promote activation of a signaling protein. Cell (2009) 2.12
Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart. J Physiol (2004) 2.09
Generation of functional ion-channel tools by E3 targeting. Nat Biotechnol (2005) 2.08
Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia (2008) 2.07
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res (2005) 2.02
Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res (2006) 2.02
Pak1 kinase homodimers are autoinhibited in trans and dissociated upon activation by Cdc42 and Rac1. Mol Cell (2002) 2.00
A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology (2004) 1.99
The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol Cell Biol (2010) 1.96
Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res (2002) 1.95
Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate (2009) 1.95
Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med (2010) 1.94
Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res (2003) 1.92
Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res (2004) 1.91
Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet (2009) 1.90
Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation (2002) 1.85
RF1 knockout allows ribosomal incorporation of unnatural amino acids at multiple sites. Nat Chem Biol (2011) 1.83
Crystal structure of human histone lysine-specific demethylase 1 (LSD1). Proc Natl Acad Sci U S A (2006) 1.80
Two independent prostate cancer risk-associated Loci at 11q13. Cancer Epidemiol Biomarkers Prev (2009) 1.78
Human LSD2/KDM1b/AOF1 regulates gene transcription by modulating intragenic H3K4me2 methylation. Mol Cell (2010) 1.73
Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet (2006) 1.70
Association of a disintegrin and metalloprotease 33 (ADAM33) gene with asthma in ethnically diverse populations. J Allergy Clin Immunol (2003) 1.69
Structural basis of selective ubiquitination of TRF1 by SCFFbx4. Dev Cell (2010) 1.68
Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation. Prostate (2010) 1.67
Promoter polymorphisms in the nitric oxide synthase 3 gene are associated with ischemic stroke susceptibility in young black women. Stroke (2005) 1.66
POT1 stimulates RecQ helicases WRN and BLM to unwind telomeric DNA substrates. J Biol Chem (2005) 1.64
Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet (2012) 1.64
Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase. Circulation (2002) 1.63
DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med (2013) 1.63
Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev (2010) 1.62
The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature (2012) 1.62
Organisation of the mouse sinoatrial node: structure and expression of HCN channels. Cardiovasc Res (2006) 1.61
Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol (2012) 1.60
A cell-free protein-producing gel. Nat Mater (2009) 1.59
Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Genes Chromosomes Cancer (2006) 1.58
Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst (2005) 1.55
A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol (2012) 1.55
Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate (2008) 1.53
Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology (2004) 1.53
Conduction slowing contributes to spontaneous ventricular arrhythmias in intrinsically active murine RyR2-P2328S hearts. J Cardiovasc Electrophysiol (2012) 1.53
An Ash2L/RbBP5 heterodimer stimulates the MLL1 methyltransferase activity through coordinated substrate interactions with the MLL1 SET domain. PLoS One (2010) 1.52
Stn1-Ten1 is an Rpa2-Rpa3-like complex at telomeres. Genes Dev (2009) 1.51
Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res (2009) 1.51
Genome-wide search for atopy susceptibility genes in Dutch families with asthma. J Allergy Clin Immunol (2002) 1.50
Hydroxyproline metabolism in mouse models of primary hyperoxaluria. Am J Physiol Renal Physiol (2011) 1.49
A novel prostate cancer susceptibility locus at 19q13. Cancer Res (2009) 1.49
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet (2012) 1.47
A support vector machine approach for detecting gene-gene interaction. Genet Epidemiol (2008) 1.46
Assembly of inflammation-related genes for pathway-focused genetic analysis. PLoS One (2007) 1.46
Endoplasmic reticulum stress induction of the Grp78/BiP promoter: activating mechanisms mediated by YY1 and its interactive chromatin modifiers. Mol Cell Biol (2005) 1.46
Genetic variants in 2q31 and 5p15 are associated with aggressive benign prostatic hyperplasia in a Chinese population. Prostate (2013) 1.45
Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst (2004) 1.44
Glyoxylate reductase activity in blood mononuclear cells and the diagnosis of primary hyperoxaluria type 2. Nephrol Dial Transplant (2006) 1.44
Dual function of Arabidopsis ATAF1 in abiotic and biotic stress responses. Cell Res (2009) 1.41
The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res (2004) 1.41
Asymmetric optical cryptosystem based on coherent superposition and equal modulus decomposition. Opt Lett (2015) 1.39
Glycolate and glyoxylate metabolism in HepG2 cells. Am J Physiol Cell Physiol (2004) 1.38
Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk. Carcinogenesis (2011) 1.37
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer (2013) 1.37